


**A New Choice in Insulin Delivery
After 88 Years from its Discovery**

ORAL-LYN®

The Novel and Unique Oral Insulin



Benta SAL Launches the Novel and Unique Oral Insulin – ORAL-LYN® in Lebanon: New Choice in Insulin Delivery After 88 Years from its Discovery

The **ORAL-LYN®** launch took place on May 14, 2009 at Le Royal Hotel in the presence of H.E. Dr. Mario Aoun and a large group of Lebanese Endocrinologists.

The launch commenced with an introduction from Mr. Bernard Tannoury, Chairman and CEO of Benta s.a.l. and from Mr. Bill Abajian, Sr. Executive Advisor for Global Strategic Alliances and Business Development, Generex Biotechnology Corp. Mr. Abajian presented Mr. Tannoury with the first canister of **ORAL-LYN®** for Lebanon, signifying the transfer of technology of the oral insulin, **ORAL-LYN®**, to Benta s.a.l.

Prof. Paolo Pozzilli, Professor of Clinical and Diabetes Research at St. Bartholomew's and The London School of Medicine, and Director of the Department of Endocrinology & Diabetes, at University Campus Bio-Medico, Rome, Italy, presented the Novel Oral Insulin, **ORAL-LYN®**, in a lecture entitled "Buccal Spray Insulin for the Treatment of Diabetes and Impaired Glucose Tolerance".



ORAL-LYN

The Novel and Unique Oral Insulin

Prof. Pozzilli stressed on the fact that insulin should be used directly after Metformin in type II diabetes due to its more beneficial effects compared to Sulfonylurea. After which, a discussion ensued with Prof. Sami Azar, Professor of Medicine, Division of Endocrinology, at American University of Beirut – Medical Center, Beirut, Lebanon and the Endocrinologists.

Prof. Sami Azar emphasized that the problem of implementing the above mentioned recommendation would be resolved with the introduction of the orally administered insulin: **ORAL-LYN®**. The patient would be more ready to accept orally administered rather than subcutaneous injectable insulin.

Buccal spray insulin, **ORAL-LYN®**, is a unique liquid aerosol formulation technology that provides a pain-free, needle-free, tasteless and convenient method of administering insulin through the oral route.

ORAL-LYN®, is available in the Lebanese market in the following form:

Each Box contains:

- 1 Canister containing 400IU of Recombinant Human Insulin Regular
- 1 Actuator – device for administering the drug



1 spray of **ORAL-LYN®** is equivalent to 1 IU of regular injectable insulin.

The Introduction of **ORAL-LYN®** shows the continuing commitment of Benta Pharma Industries to provide the patients and the medical community with new, improved medications with added value.

ORAL-LYN LAUNCH

ORAL-LYN

The Novel and Unique Oral Insulin



Press Conference at BPI:

Mr. Bill Abajian, Mr. Bernard Tannoury,
Prof. Paolo Pozzilli, Mr. Leo Ohanian



ORAL-LYN Symposium at Le Royal Hotel:

Prof. Sami Azar, Mr. Bernard Tannoury, H.E.
Dr. Mario Aoun, Prof. Paolo Pozzilli, Mr. Bill
Abajian

ORAL-LYN

The Novel and Unique Oral Insulin



ORAL-LYN Symposium at Le Royal



ORAL-LYN Symposium at Le Royal



ORAL-LYN

The Novel and Unique Oral Insulin



ORAL-LYN Dinner at Le Royal

Dr. Hosam Dib, Mr. Leo Ohanian, Dr. Walid Alameddine, Mr. Bill Abajian, Mr. Bernard Tannoury, Prof. Paolo Pozzilli



ORAL-LYN Dinner at Le Royal

BPI and Generex teams